Targeting Pla2g15 in kidney cells reduced long-chain BMP phospholipids and senescence
In this abstract, kidney tubular epithelial cells lacking the phospholipid hydrolase Pla2g15 showed reduced long-chain unsaturated BMP lipids and were protected against doxorubicin-induced senescence; the work is preclinical and the full text was not reviewed. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract reports that the lysosomal phospholipid BMP increases during kidney aging and in senescent tubular epithelial cells. [1]
In Pla2g15-deficient cells, long-chain unsaturated BMPs that accumulate during doxorubicin-induced senescence were specifically reduced, while wild-type cells showed increases. [1]
Pla2g15 knockout protected against doxorubicin-induced senescence, linked in proteomic profiling to enhanced mitochondrial metabolism. [1]
The source at a glance
- Study type / format
- Preclinical cell study reported in an abstract
- Population / context
- Kidney proximal tubular epithelial cells in preclinical experiments, including doxorubicin-induced senescence.
- Summary based on
- Study abstract
- Original publication
- September 16, 2026
Senescent kidney tubular cells and lysosomal BMP lipids
The abstract frames chronic kidney disease as a major age-related pathology driven by accumulation of chronic senescent proximal tubular epithelial cells, which promote fibrosis and functional decline. It states that senescence involves metabolic reprogramming, but the role of complex lipid metabolism in these cells remained poorly understood. The authors report that the lysosomal phospholipid bis(monoacylglycerol)phosphate (BMP) increases during kidney aging and in senescent tubular epithelial cells.
Supporting source [1]
Pla2g15 knockout, BMP species and doxorubicin senescence
Genetic knockout of the BMP hydrolase Pla2g15 in tubular epithelial cells elevated total lysophosphatidylglycerol (LPG) and BMP, with a notable shift in BMP species. Long-chain unsaturated BMPs, which accumulate during doxorubicin-induced senescence, were specifically reduced in Pla2g15-deficient cells, whereas wild-type cells showed increased levels upon senescence induction. Pla2g15 knockout also provided significant protection against doxorubicin-induced senescence. Proteomic profiling linked this protection to enhanced mitochondrial metabolism, including NAD+ metabolism and fatty acid oxidation.
Supporting source [1]
Preclinical scope of the PLA2G15 senescence findings
The authors conclude that PLA2G15 contributes to tubular epithelial cell senescence through selective BMP lipid remodelling and regulation of mitochondrial function. They suggest that targeting PLA2G15 may be a promising therapeutic strategy to prevent senescence and the associated burden of chronic kidney disease progression. These are cell-based, preclinical findings reported in an abstract; the full text was not reviewed, and the abstract does not report human outcomes or a tested treatment.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. Findings come from kidney tubular epithelial cells in preclinical experiments, including doxorubicin-induced senescence, and the abstract reports no human outcomes or tested therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Rijt SV, Denis SW, Butter LM, Schomakers BV, Ofman R, Weeghel MV, Vaz FM, Dane AD, Piersma SR, Jimenez CR, Florquin S, Gao AW, Janssens GE, Houtkooper RH, Tammaro A. · europepmc.org · September 16, 2026